Lat­est news on pa­tient death in n-of-1 CRISPR tri­al; Good news for RSV; Vac­cine R&D rev­o­lu­tion; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

This is the rare week where End­points News is mak­ing news. If you haven’t heard, Drew Arm­strong will be join­ing us from Bloomberg to be­come our new ex­ec­u­tive ed­i­tor. We are thrilled to have him on board. Read founder and ed­i­tor John Car­roll’s note about our big an­nounce­ment — and what that means for End­points.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.